BridgeMD
New treatment option for Subfertility
Official title GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
ClinicalTrials.gov ID: NCT04064840
What this study is testing
What is IVF: Decapeptyl and hCG?
IVF: Decapeptyl and hCG is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for subfertility.
Also referred to as IVF: hCG.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 42, women only
You may be able to join if
- \- Women aged \<43 years at the time of IVF treatment
You likely can't join if
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
- Women at risk of OHSS FET Inclusion criteria:
- Women aged \<43 years at the time of IVF treatment
- Replacing early cleavage embryos or blastocysts after thawing
See the full eligibility criteria
- \- Women aged \<43 years at the time of IVF treatment
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
- Women at risk of OHSS FET Inclusion criteria:
- Women aged \<43 years at the time of IVF treatment
- Replacing early cleavage embryos or blastocysts after thawing
- FET in natural cycles Exclusion criteria:
- Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 42 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.